Form 8-K - Current report:
SEC Accession No. 0000950170-25-091055
Filing Date
2025-06-27
Accepted
2025-06-27 17:28:32
Documents
18
Period of Report
2025-06-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-20250626.htm   iXBRL 8-K 76705
2 EX-1.1 achv-ex1_1.htm EX-1.1 416184
3 EX-4.1 achv-ex4_1.htm EX-4.1 336457
4 EX-5.1 achv-ex5_1.htm EX-5.1 33640
5 EX-99.1 achv-ex99_1.htm EX-99.1 24305
6 EX-99.2 achv-ex99_2.htm EX-99.2 26243
7 GRAPHIC img9551541_0.jpg GRAPHIC 12711
8 GRAPHIC img10475062_0.jpg GRAPHIC 13058
9 GRAPHIC img223336490_0.jpg GRAPHIC 16388
  Complete submission text file 0000950170-25-091055.txt   1253834

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20250626.xsd EX-101.SCH 51387
20 EXTRACTED XBRL INSTANCE DOCUMENT achv-20250626_htm.xml XML 6342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 251088059
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)